Authors


Rachel Yang

Latest:

Data Integration in the Age of Global Trials

The difference a clinical trial management system can make in integrating a global workforce.


Rachael Zuckerman

Latest:

Today's Global Site Landscape

New survey from Tufts CSDD and Applied Clinical Trials provides an inside look at global sites.


Anthony Graziosi

Latest:

Investigator Site Survey

Results reveal insight into the roles, activities, pressures, and priorities of study coordinators.


Olga Torres Gemeil, MD

Latest:

Documenting Adverse Events

Analysis of hematology and blood chemistry's AEs in sponsor's databases.


Graeme Ladds

Latest:

Is It Safe to Outsource Safety?

Knowing when to outsource and when to conduct pharmacovigilance in-house is a crucial decision.



Maria Durkin

Latest:

Improving Site Efficiency and Productivity

Real-life examples of how a clinical trial management system impacted work-life for the better at five sites.


Neil Warnock, MD

Latest:

Recruiting Diabetes Subjects

The disconnect coordinating and connecting interested patients to clinical trials is an ongoing struggle.



Markus Schmidt

Latest:

EHR and EDC Integration in Reality

An evaluation of the Munich Pilot and the affects of the EHR-EDC integration solution.


David Kerr

Latest:

Spotlight on Open-Label Extension Studies

Open-label extension (OLE) studies are common, but they do not receive as much attention as traditional Phase I through Phase IV studies. Enrollment into an OLE study typically follows enrollment into a randomized, blinded, well-controlled main study. Participants are usually informed at the time they are recruited into the main study that they may elect to enroll in an OLE study after completing the main trial. The stated objective of most OLE studies is to obtain long-term safety and tolerability data.


George Nauyok

Latest:

Waive Inclusion and Exclusion Criteria?

Waiving inclusion/exclusion criteria affects investigators, subjects, sponsors, and the trial itself.


Jules T. Mitchel, MBA, PhD

Latest:

Regulatory Considerations for Digitally Driven Trials

Tech companies entering space must adapt and adhere to regulations set by FDA.


Max Rashed

Latest:

Mastering Currency Fluctuation

Step-by-step process for budgeting global trials that uses a Currency Risk Management method.


Elia Neninger Vinejera, MD

Latest:

Documenting Adverse Events

Analysis of hematology and blood chemistry's AEs in sponsor's databases.



Michael Smyth

Latest:

Paperless Clinical Trial Optimization—Thinking Outside the Box

The implementation of best practices for clinical study and development conduct can streamline administrative burdens for investigator staff as well as study teams, and hopefully yield reduced costs in conducting global clinical development.


Denise M Langabeer

Latest:

Financial Simulation Modeling

With a PC and some software you can generate realistic projections that save time and money.


Gudrun Zahlmann

Latest:

EHR and EDC Integration in Reality

An evaluation of the Munich Pilot and the affects of the EHR-EDC integration solution.


Aliz Mathild Vega Rodriguez

Latest:

Documenting Adverse Events

Analysis of hematology and blood chemistry's AEs in sponsor's databases.



Kunal Khattar

Latest:

The Face of Partnering in India

How leveraging local expertise can make the migration east smoother for companies.


Donna Hellsten

Latest:

Planning an EDC Clinical Trial

Readers share their experiences


Julian Upton

Latest:

Engaging with Emotions: Patients as Partners

Involving patients more meaningfully in the industry's activities means getting more serious about their emotional wellbeing.


Irv Cantor

Latest:

The Quality Coach

The right person can successfully promote proper management of quality and compliance, leading to desired clinical trial outcomes.


Emma Waite

Latest:

Biomarker Boom

A look at the different testing methods and how the results impact drug development.


Kenneth Getz, MBA

Latest:

Introducing PALADIN

First-of-its-kind consortium dedicated to accelerating new medicines development through optimizing patient advocacy group—industry collaboration.


Christy Chuang-Stein

Latest:

Adaptive Designs: A Fad or the Future of Clinical Research?

Making adaptations to clinical trials in the early stages of research with the use of interim data.


Friedbert Theis, PhD

Latest:

Critical Appraisal of Clinical Quality Assurance Based on Benchmarking Results: Past - Present - Future

A follow-up survey on clinical quality assurance (CQA) assesses current industry best practices compared to a decade ago, and provides recommendations on this key component of quality management for the future.


Richard Irons

Latest:

East vs West

How cultural and training differences affect molecular-based clinical research in China.

© 2025 MJH Life Sciences

All rights reserved.